Nervous Disorder TRIZ Cases

Intravenous HMGB-1 and S100A8 proteins recruit endogenous stem cells to repair damaged tissue, avoiding scar formation from cultured skin sheets.

Formula I compounds selectively modulate the glucocorticoid receptor, treating inflammatory conditions while avoiding metabolic side effects.

Segmented PUF-nuclease entities degrade mutated alleles, overcoming delivery precision limits in Huntington's disease therapy.

Crystalline bis-miprocin fumarate enhances bioavailability while resolving formulation complexity through controlled phase transitions.

A21C/A30C disulfide bonds stabilize amyloid beta oligomers, preventing fibrillogenesis and enabling reliable drug screening for Alzheimer's disease.

A mutated HSP110 protein lacking exon 9 binds wild-type HSP110 to disrupt its anti-apoptotic function.

Segmenting the tau protein into specific phospho-peptide epitopes on liposomes improves targeting specificity while managing immunotherapy complexity.

Mutated AAV9 capsids achieve targeted gene expression in the central nervous system while minimizing peripheral off-target toxicity.

Formula I compounds inhibit CYP46A1 enzyme activity to regulate cholesterol conversion pathways.

Stepwise release of CD38 inhibitors prevents NMN degradation, increasing NAD+ levels.

Combining PPAR-gamma and Nrf2 agonists addresses toxicant-induced brain effects by modulating gene expression to inhibit neurodegeneration.

Asymmetric urea compounds modulate ghrelin receptor activity to treat obesity without affecting growth hormone levels.

Hsp20 prevents Aβ aggregation and reduces neurotoxicity by acting as an intermediary chaperone that stabilizes protein conformation.

Triptolide conjugates extend half-life and therapeutic index via protective carrier moieties.

Extracting gintonin resolves purity versus activation trade-offs, enabling neuroprotection.

Viral vector delivery of high affinity peptides targets PDZ domains, resolving pharmacokinetic trade offs in neuropathic pain treatment.

CH1 and CL domain charge engineering directs heterodimer formation, eliminating Bence-Jones side products and proteolytic cleavage risks.

Prophylactic GGF2 administration prevents fibrosis and muscle atrophy following peripheral nerve injury.

Cleaved peptides neutralize amyloid beta aggregates, resolving the trade-off between therapeutic efficacy and side effects in Alzheimer's treatment.

Masitinib mitigates disability accumulation by targeting mitochondrial dysfunction, addressing the limited efficacy of existing therapies.

Bifunctional CDM-H molecules link a gp120 binding terminus to a cytotoxic agent via a labile linker.

Crystalline axelopran sulfate solid composition stabilizes the peripheral mu opioid antagonist within a combination dosage form.

Antibodies bind HER3 conformational epitopes across domains two and four to stabilize inactive receptor states.

DNA aptamers bind alpha-synuclein monomers into stable complexes, reducing fibrilization in neurodegenerative disease models.

Segmenting autism spectrum disorder by metabolic pathways enables reproducible molecular diagnostics and targeted gut microbiota therapies.

A self-emulsifying pharmaceutical composition combines eicosapentaenoic acid ethyl ester with statins using specific emulsifier ratios.

Antibody-coding RNA molecules deliver genetic instructions for in vivo therapeutic protein production, avoiding DNA integration risks.

Chimeric peptides target IGF-1 and its receptors to overcome variable receptor expression across tumor types.

Nitrogen-containing compounds inhibit NLRP3 via structural optimization, resolving low specificity and safety risks in autoimmune treatments.

Specific CDR sequences enhance ITIM phosphorylation to control B cell activation without cross-reactions.

Anti-amyloid beta antibodies target responsive patients through tau burden and APOE e4 allele stratification.

Highly purified cannabidiol reduces seizure frequency in patients with ZDHHC9 gene mutations.

Living probiotic bacteria produce endogenous folate to normalize elevated plasma homocysteine concentrations associated with cardiovascular risks.

Fc-tagged PSG1 shifts microglia from pro-inflammatory to anti-inflammatory states, accelerating remyelination and behavioral recovery in stroke models.

Amyloid-binding peptides destroy SEVI fibrils to reduce HIV infection efficiency, avoiding lifelong antiretroviral therapy side effects.

Optimizing pH to 5.5-7.0 with mannitol stabilizes high-concentration glatiramer acetate, reducing injection volume while maintaining therapeutic effectiveness.

A magnetic torquer conjugate drug transmits rotational force to target proteins via a controlled rotating magnetic field.

Fibrillar collagen matrix holds bupivacaine hydrochloride for controlled release at the surgical site.

Segmented tablet architecture resolves manufacturing precision trade-offs to achieve precise triple combination release of active agents.

Elongated tubular hydrogel construct bridges disconnected neural regions to restore long-distance axonal connections lost after injury.

A stable liquid pharmaceutical composition containing curcumin, surfactant, solvent, and oil.

Lipid conjugates facilitate high-efficiency loading of cannabidiol into extracellular vesicles, reducing waste during targeted delivery.

Administering ghrelin derivatives accelerates recovery speed by improving physiological conditions, reducing hospitalization duration.

Conjugating therapeutic enzymes to transferrin enables receptor-mediated transport across the blood-brain barrier.

WRW4 peptide antagonists block FPRL1 receptor binding to reduce excessive phagocytic cell recruitment and tissue damage.